USPSTF: Evidence Lacking for Lipid Screening in Children, Teens

Share this content:
USPSTF: Evidence Lacking for Lipid Screening in Children, Teens
USPSTF: Evidence Lacking for Lipid Screening in Children, Teens

TUESDAY, Aug. 9, 2016 (HealthDay News) -- The U.S. Preventive Services Task Force (USPSTF) has concluded that the evidence is currently insufficient to weigh the balance of benefits and harms of screening for lipid disorders in children and adolescents (aged 20 years or younger). These findings form the basis of a final recommendation statement published in the Aug. 9 issue of the Journal of the American Medical Association.

Researchers from the USPSTF updated the 2007 recommendations on screening for lipid disorders in children, adolescents, and young adults. They reviewed the evidence, with one review focusing on screening for heterozygous familial hypercholesterolemia and one focused on screening for multifactorial dyslipidemia.

The researchers found that there was limited evidence on the quantitative difference in diagnostic yield between universal and selective screening approaches, the effectiveness and harms of long-term treatment and screening, and the correlation between changes in intermediate outcomes and improvements in adult cardiovascular health outcomes. Based on these findings, the USPSTF concluded that there was insufficient evidence to weigh the balance of benefits and harms of lipid screening.

"In the absence of evidence, health care professionals should continue to take each patient's individual risks and circumstances [into] consideration, and use their best judgment when deciding whether or not to screen," Task Force vice chair David Grossman, M.D., M.P.H., said in a statement.

Recommendation Statement
Evidence Review 1
Evidence Review 2
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Belimumab Aids Anti-dsDNA, Hypocomplementemic Lupus

Belimumab Aids Anti-dsDNA+, Hypocomplementemic Lupus

More SLE Responder Index responders at week 52 in the belimumab group versus the placebo group

Too Few Adults Taking Epilepsy Meds Have Seizure Control

Too Few Adults Taking Epilepsy Meds Have Seizure ...

Ninety percent of those with active epilepsy take meds; 44 percent of those report seizure control

Pediatric Exposures to Liquid Nicotine Down From 2015 to 2016

Pediatric Exposures to Liquid Nicotine Down From 2015 ...

Still poses serious risk to children; decrease likely in part to law requiring child-resistant packaging

is free, fast, and customized just for you!

Already a member?

Sign In Now »